Cand.med., Ph.d. student Gayaththri Vimalathas Department of Pathology, OUH
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
Monitoring circulating tumor DNA in aggressive large B-cell lymphoma - a tool for personalized medicine
The aim of this project is to explore the potential utility of circulating tumor DNA as a new molecular marker of minimal residual disease in patients with aggressive large B-cell lymphoma (diffuse large B-cell lymphoma and high grade B-cell lymphoma). The project comprises 4 work packages in which we want to optimize a clinically applicable Next Generation Sequencing-based method to detect residual disease in blood samples by using ctDNA as an easily accesible and minimally invasive method.
The aim of this project is to evaluate the potential utility of circulating tumor DNA (ctDNA) assessed by Next Generation Sequencing (NGS) as a novel molecular marker of minimal residual disease (MRD) in patients with aggressive large B-cell lymphoma. It is incented by a lack in specific and sensitive markers of MRD in diffuse large B-cell lymphomas (DLBCL) and high-grade B-cell lymphomas, in which a sizable subset of patients eventually will relapse.
Current response assessment standards entail PET and/or CT imaging followed by routine clinical follow-up and surveillance CT. A significant number of these scans present inconclusive findings, which challenge clinical
assessment and decision-making on subsequent choice of therapy or surveillance. Thus, there is an unmet need for novel, readily accessible molecular biomarkers for earlier and more accurate identification of MRD and subclinical relapse.
Description of the cohort
This project includes patients with aggressive large B-cell lymphoma comprising the diagnostic entities diffuse large B-cell lymphoma and high-grade B-cell lymphoma. The patients have recieved treatment at the Department of Hematology, OUH.
Data and biological material
Formalin-fixed paraffin-embedded diagnostic and relapse tissue material and plasma samples.
Data from patient charts, pathology reports, and The Danish Lymphoma Database will be utilized during the project.
Collaborating researchers and departments
Department of Hematology, OUH
Overlæge Thomas Stauffer Larsen
Hematology-Pathology Research Laboratory, Department of Hematology, OUH
Professor Charlotte Guldborg Nyvold
Department of Pathology, OUH
Overlæge Michael Boe Møller
Afdelingsmolekylærbiolog Thomas Kielsgaard Kristensen